Gaina Gisela, Popa Gruianu Alexandra
Laboratory of Cell Biology, Neuroscience and Experimental Myology, 'Victor Babes' National Institute of Pathology, 050096 Bucharest, Romania.
Department of Biochemistry and Molecular Biology, University of Bucharest, 050095 Bucharest, Romania.
Exp Ther Med. 2021 Jun;21(6):610. doi: 10.3892/etm.2021.10042. Epub 2021 Apr 14.
The muscular dystrophies are a heterogeneous group of genetically inherited diseases characterized by muscle weakness and progressive wasting, which can cause premature death in severe forms. Although >30 years have passed since the identification of the first protein involved in a type of muscular dystrophy, there is no effective treatment for these disabling disorders. In the last decade, several novel therapeutic approaches have been developed and investigated as promising therapeutic approaches aimed to ameliorate the dystrophic phenotype either by restoring dystrophin expression or by compensating for dystrophin deficiency. Concurrently, with the development of therapeutic approaches, in addition to naturally occurring animal models, a wide range of genetically engineered animal models has been generated. The use of animals as models of muscular dystrophies has greatly improved the understanding of the pathogenicity of these diseases and has proven useful in gene therapy studies. In this review, we summarize these latest innovative therapeutic approaches to muscular dystrophies and the usefulness of the various most common experimental animal models.
肌营养不良症是一组遗传异质性疾病,其特征为肌肉无力和进行性萎缩,严重时可导致过早死亡。尽管自首次鉴定出与一种肌营养不良症相关的蛋白质以来已过去30多年,但这些致残性疾病仍无有效治疗方法。在过去十年中,已开发并研究了几种新的治疗方法,作为有前景的治疗手段,旨在通过恢复肌营养不良蛋白表达或补偿肌营养不良蛋白缺乏来改善营养不良表型。同时,随着治疗方法的发展,除了天然存在的动物模型外,还产生了广泛的基因工程动物模型。将动物用作肌营养不良症的模型极大地增进了对这些疾病致病性的理解,并已证明在基因治疗研究中有用。在本综述中,我们总结了这些针对肌营养不良症的最新创新治疗方法以及各种最常见实验动物模型的用途。